1-(3-溴苯基)-1-甲基乙胺盐酸盐 | 676135-18-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(3-溴苯基)-1-甲基乙胺盐酸盐
• 英文名称: 2-(3-bromophenyl)propan-2-amine hydrochloride
• 英文别名: 2-(3-bromophenyl)propan-2-amine;hydrochloride
• CAS: 676135-18-5
• 化学式: C₉H₁₂BrN*ClH
• 分子量: 250.566
• InChiKey: UXGIUUWHZBFBAK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.06
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 海关编码：
  2921499090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  1-(3-溴苯基)-1-甲基乙胺盐酸盐 在 palladium diacetate 、 sodium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 水 为溶剂， 反应 0.42h， 生成 1-azabicyclo[2.2.2]oct-3-yl [2-(4'-fluorobiphenyl-3-yl)propan-2-yl]carbamate
  参考文献：
  名称：

  Facile synthesis of the glucosylceramide synthase inhibitor GZ667161

  摘要：

  GZ667161 (GZ-161) is a quinuclidine-based small molecule inhibitor of the lysosomal enzyme glucosylceramide synthase. It represents an important tool molecule for studying the contribution of glycosphingolipids to disease pathology in lysosomal storage disorders such as Gaucher disease and GBA1 Parkinson's disease. GZ667161 is not commercially available. The published synthesis involves 6 steps and proceeds in 18% overall reported yield. As part of a drug discovery program targeting Type 2 Gaucher disease we required quantities of GZ667161 that would support animal studies. To facilitate the project, we devised and executed an efficient 4-step convergent synthesis of the compound. (C) 2020 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2020.152352
• 作为产物：
  描述：

  3-溴苯甲酸甲酯 在 盐酸 、 硫酸 、 溶剂黄146 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 生成 1-(3-溴苯基)-1-甲基乙胺盐酸盐
  参考文献：
  名称：

  Facile synthesis of the glucosylceramide synthase inhibitor GZ667161

  摘要：

  GZ667161 (GZ-161) is a quinuclidine-based small molecule inhibitor of the lysosomal enzyme glucosylceramide synthase. It represents an important tool molecule for studying the contribution of glycosphingolipids to disease pathology in lysosomal storage disorders such as Gaucher disease and GBA1 Parkinson's disease. GZ667161 is not commercially available. The published synthesis involves 6 steps and proceeds in 18% overall reported yield. As part of a drug discovery program targeting Type 2 Gaucher disease we required quantities of GZ667161 that would support animal studies. To facilitate the project, we devised and executed an efficient 4-step convergent synthesis of the compound. (C) 2020 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2020.152352
• 作为试剂：
  描述：

  N-(2-(3-bromophenyl)propan-2-yl)-2-chloroacetamide 、 溶剂黄146 在 乙酸乙酯 、 sodium hydroxide 、 Sodium sulfate-III 、 crude material 、 盐酸1,4-二恶烷 、 1-(3-溴苯基)-1-甲基乙胺盐酸盐 、 乙醚 作用下， 以 乙醇 为溶剂， 反应 18.0h， 生成 1-(3-溴苯基)-1-甲基乙胺盐酸盐
  参考文献：
  名称：

  Glucosylceramide synthase inhibitors

  摘要：

  该发明涉及抑制葡糖鞘氨醇合成酶（GCS）的抑制剂，可用于治疗代谢性疾病，如溶酶体贮积症，单独或与酶替代治疗结合使用，并用于治疗癌症。

  公开号：

  US09139580B2

文献信息

• [EN] GLUCOSYLCERAMIDE SYNTHASE INHIBITORS<br/>[FR] INHIBITEURS DE LA GLUCOSYLCÉRAMIDE SYNTHASE
  申请人：GENZYME CORP

  公开号：WO2015089067A1

  公开（公告）日：2015-06-18

  The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy.

  该发明涉及对葡萄糖酰胺合成酶（GCS）的抑制剂，用于治疗代谢性疾病，如溶酶体贮积病，可以单独应用或与酶替代疗法结合使用。
• 2-Amino- and 2-thio- substituted 1,3-diaminopropanes
  申请人：Hom Roy

  公开号：US20050267199A1

  公开（公告）日：2005-12-01

  Disclosed are compounds of the formula: where variables Q, Z, X, R 15 , R 2 , R 3 , and R c are defined herein. Compounds disclosed herein are inhibitors of the beta-secretase enzyme and are therefore useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal.

  本发明揭示了以下式子的化合物：其中变量Q、Z、X、R15、R2、R3和R4在此定义。本发明揭示的化合物是β-分泌酶酶的抑制剂，因此在治疗老年痴呆症和其他以哺乳动物体内A beta 肽沉积为特征的疾病中有用。
• Acetyl 2-hydroxy-1, 3-diaminoalkanes
  申请人：——

  公开号：US20040180939A1

  公开（公告）日：2004-09-16

  Disclosed are compounds of the formula: 1 where variables Z, X, R 15 , R 2 , R 3 , and R c are defined herein. Compounds disclosed herein are inhibitors of the beta-secretase enzyme and are therefore useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal.

  本发明揭示了公式1的化合物：其中变量Z、X、R15、R2、R3和Rc的定义如下。本发明所揭示的化合物是β-分泌酶酶的抑制剂，因此在治疗老年痴呆症和其他以A beta肽在哺乳动物中沉积为特征的疾病方面有用。
• 2-amino- and 2-thio- substituted 1,3-diaminopropanes
  申请人：Elan Pharmaceuticals, Inc.

  公开号：US07544717B2

  公开（公告）日：2009-06-09

  Disclosed are compounds of the formula: where variables Q, Z, X, R15, R2, R3, and Rc are defined herein. Compounds disclosed herein are inhibitors of the beta-secretase enzyme and are therefore useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal.

  本发明涉及公式如下的化合物：其中变量Q、Z、X、R15、R2、R3和Rc在此定义。本发明中所披露的化合物是β-分泌酶酶的抑制剂，因此在治疗阿尔茨海默病和其他以哺乳动物中A beta肽沉积为特征的疾病中有用。
• ACETYL 2-HYDROXY-1,3-DIAMINOALKANES
  申请人：John Varghese

  公开号：US20100145056A1

  公开（公告）日：2010-06-10

  Disclosed are compounds of the formula: where variables Z, X, R 15 , R 2 , R 3 , and R c are defined herein. Compounds disclosed herein are inhibitors of the beta-secretase enzyme and are therefore useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal.

  公开了以下式子的化合物：其中变量Z，X，R15，R2，R3和R4在此处定义。本文所披露的化合物是β-分泌酶酶的抑制剂，因此在治疗阿尔茨海默病和其他以A beta肽在哺乳动物中沉积为特征的疾病中有用。